Table 2.
Downs and black assessment.
| Study | Total Scores | Risk of bias |
|---|---|---|
| Stone et al. (6) (RAVE) | 20 | Medium |
| Specks et al. (7) (extension of RAVE) | 18 | Medium |
| Miloslavsky et al. (8) (open-label extension of RAVE) | 13 | High |
| Jones et al. (9) (RITUXVAS) | 20 | Medium |
| Jones et al. (10) (extension of RITUXVAS) | 17 | Medium |
| Berden et al. (5) (substudy of RITUXVAS) | 15 | Medium |
| De Menthon et al. (11) | 14 | High |
| Guillevin et al. (12) (MAINRITSAN) | 18 | Medium |
| Charles et al. (13) (MAINRITSAN2) | 20 | Medium |
| Erkan et al. (14) (RITAPS) | 18 | Medium |
| Birgens et al. (15) | 22 | Low |
| Michel et al. (16) (RAIHA) | 23 | Low |
| Burak et al. (17) | 14 | High |
| Davatchi et al. (18) | 16 | Medium |
| Hall et al. (19) | 13 | High |
| Levi et al. (4) | 11 | High |
| Busse et al. (3) | 10 | High |
| Marcelin et al. (24) | 18 | Medium |
| Ide et al. (23) | 17 | Medium |
| Bower et al. (21) | 19 | Medium |
| Gerard et al. (22) | 18 | Medium |
| Powles et al. (26) | 12 | High |
| Bestawros et al. (20) | 12 | High |
| Peker et al. (25) | 4 | High |
| Uldrick et al. (27) | 17 | Medium |
| Dammacco et al. (28) | 26 | Low |
| De Vita et al. (29) | 21 | Low |
| Quartuccio et al. (31) (Follow-up of De Vita et al.) | 16 | Medium |
| Sneller et al. (30) | 28 | Low |
| Oddis et al. (48) (RIM trial) | 25 | Low |
| Ravani et al. (70) | 25 | Low |
| Ravani et al. (67) | 17 | Medium |
| Magnasco et al. (69) | 24 | Low |
| Iijima et al. (68) | 27 | Low |
| Ravani et al. (71) | 23 | Low |
| Basu et al. (72) (RITURNS) | 26 | Low |
| Dahan et al. (51) | 23 | Low |
| Lafayette et al. (35) | 23 | Low |
| Shah et al. (32) | 5 | High |
| Salvi et al. (33) | 21 | Low |
| Stan et al. (34) | 24 | Low |
| Khosroshahi et al. (37) | 8 | High |
| Khosroshahi et al. (38) | 16 | Medium |
| Carruthers et al. (36) | 17 | Medium |
| Yamamoto et al. (39) | 8 | High |
| Quattrocchio et al. (40) | 12 | High |
| Hasan et al. (45) (only considering Part 2) | 5 | High |
| Zaja et al. (47) | 20 | Medium |
| Li et al. (46) | 23 | Low |
| Arnold et al. (41) | 27 | Low |
| Gudbrandsdottir et al. (44) | 21 | Low |
| Dai et al. (42) | 11 | High |
| Ghanima et al. (43) (RITP trial) | 25 | Low |
| Narvaez et al. (49) | 6 | High |
| Alexeeva et al. (50) | 16 | Medium |
| Merrill et al. (103) (EXPLORER trial) | 27 | Low |
| Rovin et al. (104) (LUNAR trial) | 23 | Low |
| Zhang et al. (105) | 10 | High |
| Andrade-Ortega et al. (106) | 19 | Medium |
| Hauser et al. (53) | 21 | Low |
| Hawker et al. (54) | 27 | Low |
| Komori et al. (55) (RIVITALISE trial) | 21 | Low |
| Illa et al. (58) | 14 | High |
| Lebrun et al. (60) | 12 | High |
| Nelson et al. (62) | 5 | High |
| Stieglbauer et al. (63) | 7 | High |
| Lindberg et al. (61) | 9 | High |
| Diaz-Manera et al. (57) | 16 | Medium |
| Sun et al. (64) | 14 | High |
| Anderson et al. (56) | 16 | Medium |
| Beecher et al. (65) (extension trial of Anderson et al.) | 13 | High |
| Lebrun et al. (59) | 17 | Medium |
| Jing et al. (66) | 19 | Medium |
| Nikoo et al. (73) | 23 | Low |
| Joly et al. (75) (Ritux 3) | 25 | Low |
| Song et al. (101) | 17 | Medium |
| Song et al. (102) [Follow-up trial of Song et al. (101)] | 15 | Medium |
| Jimenez-Boj et al. (100) | 15 | Medium |
| Daoussis et al. (107) | 21 | Low |
| Leiper et al. (108) | 25 | Low |
| Dass et al. (95) | 22 | Low |
| Meijer et al. (97) | 27 | Low |
| Devauchelle-Pensec et al. (96) (TEARS trial) | 26 | Low |
| Bowman et al. (98) (TRACTISS) | 26 | Low |
| Fisher et al. (99) (substudy of TRACTISS) | 25 | Low |
| Edwards et al. (77) | 26 | Low |
| Strand et al. (88) [2 year follow-up of Edwards et al. (77)] | 22 | Low |
| Cohen et al. (76) (REFLEX trial) | 26 | Low |
| Keystone et al. (90) (substudy of the REFLEX trial) | 26 | Low |
| Emery et al. (79) (DANCER trial) | 25 | Low |
| Owczarczyk et al. (83) | 12 | High |
| Emery et al. (78) (SERENE trial) | 24 | Low |
| Mease et al. (82) (SUNRISE trial) | 26 | Low |
| Greenwald et al. (80) (TAME trial) | 22 | Low |
| Tak et al. (93) (IMAGE trial) | 25 | Low |
| Tak et al. (89) (Extension of the IMAGE trial) | 26 | Low |
| Mariette et al. (81) (SMART trial) | 22 | Low |
| Vital et al. (94) | 23 | Low |
| Peterfy et al. (84) (RA-SCORE trial) | 25 | Low |
| Porter et al. (85) (ORBIT trial) | 24 | Low |
| Wijesinghe et al. (86) | 23 | Low |
| Brown et al. (87) (SWITCH RCT) | 22 | Low |
| Rubbert-Roth et al. (92) | 28 | Low |
| Bingham et al. (91) | 14 | High |
| Kanwar et al. (74) | 20 | Medium |